Zinc oxide nanoparticles and a standard antidiabetic drug restore the function and structure of beta cells in Type-2 diabetes

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 810-820

  El Gharbawy, Rehab Mohmed ^a   Emara, Ashraf Mahmoud ^b   Abu Risha, Sally El Sayed ^a  

^a Tanta University   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

Dipeptidyl peptidase IV; miR 103; miR 143; Streptozotocin; Type 2 diabetes; Zinc oxide nanoparticles

Indexed keywords

FRUCTOSAMINE; GLUCOSE; INSULIN; MICRORNA; MICRORNA 103; MICRORNA 143; PANCREAS ENZYME; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ZINC OXIDE NANOPARTICLE; ANTIDIABETIC AGENT; NANOPARTICLE; ZINC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL STRUCTURE; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FRUCTOSAMINE BLOOD LEVEL; GENE EXPRESSION; GLUCOSE TOLERANCE; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREATIC TISSUE; PRIORITY JOURNAL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THERANOSTIC NANOMEDICINE; TREATMENT DURATION; WEIGHT REDUCTION; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; PHYSIOLOGY; RANDOMIZATION; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; NANOPARTICLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; ZINC OXIDE;

EID: 84991517920     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.09.068     Document Type: Article

References (61)

1. [1] Berry, C., Tardif, J.-C.M., Bourassa, G., Coronary heart disease in patients with diabetes. J. Am. Coll. Cardiol. 49 (2007), 631–642.
2. [2] Powell, S.R., The antioxidant properties of zinc. J. Nutr. 130 (2000), 1447S–1454S.
3. [3] Adachi, Y., Yoshida, J., Kodera, Y., Kiss, T., Jakusch, T., Enyedy, E.A., Yoshikawa, Y., Sakurai, H., Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes. Biochem. Biophys. Res. Commun. 351 (2006), 165–170.
4. [4] Reaven, G.M., Role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
5. [5] Cai, L., Li, X.K., Song, Y., Cherian, M.G., Essentiality, toxicology and chelation therapy of zinc and copper. Curr. Med. Chem. 12 (2005), 2753–2763.
6. [6] Reid, T.S., Practical use of glucagon-Like peptide-1 receptor agonist therapy in primary care. Clin. Diabetes 31 (2013), 148–157.
7. [7] Nauck, M.A., Meier, J.J., Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul. Pept. 128 (2005), 135–148.
8. [8] Esguerra, J.L., Bolmeson, C., Cilio, C.M., Eliasson, L., Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto–Kakizaki rat. PLoS One, 6, 2011, e18613.
9. [9] Bhatia, P., Raina, S., Chugh, J., Sharma, S., miRNAs: early prognostic biomarkers for Type 2 diabetes mellitus?. Biomarkers Med. 9:10 (2015), 1025–1040.
10. [10] Kloosterman, W.P., Plasterk, R.H., The diverse functions of microRNAs in animal development and disease. Dev. Cell 11 (2006), 441–450.
11. [11] Sayari, A., EI Mir, L., Structural and characterization of Ni and Al Co-doped ZnO nanopowders synthesized via the sol-gel process. Kona Powder Part. J. 32 (2015), 154–162.
12. [12] Srinivasan, K., Viswanand, B., Asrat, L., Kaul-Ramarao, C.L., Combination of high-fat diet-fed and low dose of streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52 (2005), 313–320.
13. [13] Mahmoud, A.M., Ahmed, O.M., Abdel-Moneim, A., Ashour, M.B., Upregulation of PPARγ mediates the antidiabetic effects of citrus flavonoids in type 2 diabetic rats. Inte. J. Bioassays 2 (2013), 756–761.
14. [14] Jin, H.Y., Liu, W.J., Park, J.H., Baek, H.S., Park, T.S., Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch. Med. Res., 40, 2010, 536e544.
15. [15] Trinder, P., Determination of glucose in blood using glucoseoxidase with an alternative oxygen acceptor. Ann. Clin. Biochem. 6 (1969), 24–27.
16. [16] Little, R.R., Wiedmeyer, H.M., England, J.D., Wilke, A.L., Rohlfing, C.L., Wians, F.H., Jacobson, J.M., Zellmer, V., Godstein, D.E., Interlaboratory standardization of measurements of glycohemoglobins. Clin. Chem. 38 (1992), 2472–2478.
17. [17] Schuster, H.G., Pilz, K., Colorimetric micromethod for the determination of nonesterified long-chain fatty acids in serum. Z. Med. Lab. Diagn. 20 (1979), 212–217.
18. [18] Deeg, R., Ziegenohrm, J., Kinetic enzymatic method for automated determination of total cholesterol in serum. J. Clin. Chem. 29 (1983), 1798–1802.
19. [19] Fossati, P., Prencipe, L., Serum triglycerides determined colourimetrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 28 (1982), 2077–2080.
20. [20] Burstein, M., Scholnick, H.R., Morfin, R., Rapid method for the isolation of lipoproteins for human serum by precipitation with polyanions. J. Lipid Res. 11 (1970), 583–595.
21. [21] Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:6 (1972), 499–502.
22. [22] Nobert, W.T., Clinical Guide to Laboratory Tests. 3rd edition, 1995, W.B. Saunders Co., Philadelphia, PA.
23. [23] Yamanaka, N., Nishida, K., Ota, R., Increase of superoxide dismutase activity in various human leukemia cells. Physiol. Chem. Phys. 11 (1979), 253–256.
24. [24] Sun, Y., Oberley, L.W., Li, Y., A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34:3 (1988), 497–500.
25. [25] Banchroft, J.D., Stevens, A., Turner, D.R., Theory and Practice of Histologic Techniques. 4th ed., 1996, Churchill Livingstone, New York/London/San Francisco/Tokyo.
26. [26] Frank, B., Globalization of Diabetes.The role of diet, lifestyle, and genes. Diabetes Care 34 (2011), 1249–1257.
27. [27] Zafar, M., Naqvi, S.N., Effects of STZ-Induced diabetes on the relative weights of kidney, liver and pancreas in albino rats: a comparative study. Int. J. Morphol. 28 (2010), 135–142.
28. [28] Rave, K., Nosek, L., Posner, J., Heise, T., Roggen, K., van Hoogdalem, E.J., Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes: results of a hyperglycaemic glucose clamp study. Nephrol. Dial. Transplant. 21 (2006), 2166–2171.
29. [29] Davidson, E.P., Coppey, L.J., Dake, B., Yorek, M.A., Treatment of streptozotocin-Induced diabetic rats with alogliptin: effect on vascular and neural complications. Exp. Diabetes Res. 2011 (2011), 1–7.
30. [30] Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107 (2010), 810–817.
31. [31] Vatandoost, N., Amini, M.B., Iraj, B., Momenzadeh, S., Salehi, R., Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats. Gene 572 (2015), 95–100.
32. [32] Wilfred, B.R., Wang, W.X., Nelson, P.T., Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 91 (2007), 209–217.
33. [33] Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M.H., Stoffel, M., MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474 (2011), 649–653.
34. [34] Li, S., Chen, X., Zhang, H., Liang, X., Xiang, Y., Yu, C., Zen, K., Li, Y., Zhang, C.Y., Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J. Lipid Res. 50 (2009), 1756–1765.
35. [35] Jordan, S.D., Krüger, M., Willmes, D.M., Redemann, N., Wunderlich, F.T., Brönneke, H.S., Merkwirth, C., Kashkar, H., Olkkonen, V.M., Böttger, T., Braun, T., Seibler, J., Brüning, J.C., Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat. Cell Biol. 3 (2011), 434–446.
36. [36] Tahara, A., Matsuyama-Yokono, A., Nakano, R., Someya, Y., Hayakawa, M., Shibasaki, M., Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol. Rep. 61:5 (2009), 899–908.
37. [37] Thornberry, N.A., Gallwitz, B., Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract. Res. Clin. Endocrinol. Metab. 23 (2009), 479–486.
38. [38] Jansen, J., Karges, W., Rink, L., Zinc and diabetes—Clinical links and molecular mechanisms. J. Nutr. Biochem. 20 (2009), 399–417.
39. [39] Alkaladi, A., Abdelazim, A.M., Afifi, M., Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-Induced diabetic rats. Int. J. Mol. Sci. 15 (2014), 2015–2023.
40. [40] Richards-Williams, C., Contreras, J.L., Berecek, K.H., Schwiebert, E.M., Extracellular ATP and zinc are co-secreted with insulin and activate multiple P2X purinergic receptor channels expressed by islet beta-cells to potentiate insulin secretion. Purinergic Signal. 4 (2008), 393–405.
41. [41] Koga, M., Hashimoto, K., Murai, J., et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin. Chim. Acta 412 (2011), 253–257.
42. [42] Ali, M.A., El-Abhar, H.S., Kamel, M.A., Attia, A.S., Antidiabetic effect of galantamine: novel effect for a known centrally acting drug. PLoS One, 10, 2015, e0134648.
43. [43] Yavropoulou, M.P., Pikilidou, M., Kotsa, K., Michopoulos, A., Papakonstantinou, E., Yovos, J.G., Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. J. Diabetes Metab. Disord. 22 (2015), 14–68.
44. [44] Ravi, K., Rajasekaran, S., Subramanian, S., Antihyperlipidemia effect of Eugenia jambolana seed kernel on streptozotocin-induced diabetes in rats. Food Chem. Toxicol. 43 (2005), 1433–1439.
45. [45] Tan, B.K.H., Tan, C.H., Pushparaj, P.N., Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed streptozotocin-induced diabetic rats. Life Sci. 76 (2005), 2827–2839.
46. [46] Zhang, W., Zhao, J., Wang, J., Pang, X., Zhuang, X., Zhu, X., Qu, W., Hypoglycemic effect of aqueous extract of sea buckthorn (Hippophae rhamnoides L.) seedresidues in streptozotocin-induced diabetic rats. Phytother. Res. 24 (2010), 228–232.
47. [47] Adiels, M., Taskinen, M.R., Packard, C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49 (2006), 755–762.
48. [48] Hsieh, J., Longuet, C., Baker, C.L., et al. The glucagon like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53 (2010), 552–561.
49. [49] Ranasinghe, P., Wathurapatha, W.S., Ishara, M.H., Jayawardana, R., Galappatthy, P., Katulanda, P., Constantine, G.R., Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis. Nutr Metab (Lond.), 2, 2015, 26.
50. [50] Brewer, G.J., Yuzbasiyan-Gurkan, V., Johnson, V., Treatment of Wilson's disease with zinc. IX: Response of serum lipids. J. Lab. Clin. Med. 118:Nov (5) (1991), 466–470.
51. [51] Quilliot, D., Dousset, B., Guerci, B., Dubois, F., Drouin, P., Ziegler, O., Evidence that diabetes mellitus favors impaired metabolism of zinc, copper, and selenium in chronic pancreatitis. Pancreas 22 (2001), 299–306.
52. [52] Crouch, R.K., Gandy, S.E., Kimsey, G., Galbraith, R.A., Galbraith, G.M.P., Buse, M.G., The inhibition of islet superoxide dismutase by diabetogenic drugs. Diabetes 30 (1981), 235–241.
53. [53] Saltiel, A.R., Kahn, C.R., Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414 (2001), 799–806.
54. [54] Gurgul, E., Lortz, S., Tiedge, M., Jörns, A., Lenzen, S., Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines. Diabetes 53 (2004), 2271–2280.
55. [55] Ávila Dde, L., Araújo, G.R., Silva, M., Miranda, P.H., Diniz, M.F., Pedrosa, M.L., et al. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type1 diabetic rats. Arch. Med. Res. 44:3 (2013), 194–202.
56. [56] Overbeck, S., Rink, L., Haase, H., Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Arch. Immunol The. Exp. 56 (2008), 15–30.
57. [57] Shirwaikar, A., Rajendran, K., Barik, R., Effect of aqueous bark extract of Garuga pinnata Roxb. in streptozotocin-nicotinamide induced type-II diabetes mellitus. J. Ethnopharmacol. 107 (2006), 285–290.
58. [58] Han, S.H., Jeon, J.H., Ju, H.R., Jung, U., Kim, K.Y., et al. VDUP1 upregulated byTGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22 (2003), 4035–4046.
59. [59] Jörns, A., Kubat, B., Tiedge, M., Wedekind, D., Hedrich, H.J., et al. Pathology of the pancreas and other organs in the diabetic LEW. 1AR1/Ztm-iddm rat, a new model of spontaneous insulin-dependent diabetes mellitus. Virchows Arch. 444 (2004), 183–189.
60. [60] Sjoholm, A., Diabetes mellitus and impaired pancreatic β-cell proliferation. J. Intern. Med. 239 (1996), 211–220.
61. [61] Slepchenko, K.G., James, C.B., Li, Y.V., Inhibitory effect of zinc on glucose-stimulated zinc/insulin secretion in an insulin-secreting β-cell line. Exp. Physiol. 98 (2013), 1301–1311.